243 related articles for article (PubMed ID: 32656741)
1. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
2. Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.
Matrka MC; Cimperman KA; Haas SR; Guasch G; Ehrman LA; Waclaw RR; Komurov K; Lane A; Wikenheiser-Brokamp KA; Wells SI
PLoS Genet; 2018 Mar; 14(3):e1007227. PubMed ID: 29538372
[TBL] [Abstract][Full Text] [Related]
3. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
4. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
5.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
6. DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM; Morreale RJ; Morris TA; Mintz-Cole RA; Hoskins EE; Balsitis SJ; Husseinzadeh N; Witte DP; Wikenheiser-Brokamp KA; Lambert PF; Wells SI
Am J Pathol; 2009 Jan; 174(1):71-81. PubMed ID: 19036808
[TBL] [Abstract][Full Text] [Related]
7. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
8. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
9. DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.
Adams AK; Hallenbeck GE; Casper KA; Patil YJ; Wilson KM; Kimple RJ; Lambert PF; Witte DP; Xiao W; Gillison ML; Wikenheiser-Brokamp KA; Wise-Draper TM; Wells SI
Oncogene; 2015 Feb; 34(7):868-77. PubMed ID: 24608431
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
[No Abstract] [Full Text] [Related]
12. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
13. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
14. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
15. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
16. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
[TBL] [Abstract][Full Text] [Related]
17. First Report of Thoracic Carcinoma With DEK::AFF2 Rearrangement: A Case Report.
Savari O; Chang JC; Bishop JA; Sakthivel MK; Askin FB; Rekhtman N
J Thorac Oncol; 2022 Aug; 17(8):1050-1053. PubMed ID: 35773081
[TBL] [Abstract][Full Text] [Related]
18. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
19. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
20. DEK::AFF2 Fusion Carcinomas of Head and Neck.
Ruangritchankul K; Sandison A
Adv Anat Pathol; 2023 Mar; 30(2):86-94. PubMed ID: 36221219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
